Good point. And let's also think about what happens if we do successfully show a reduction of mortality in these severe and critical patients. Now we're on the market as the only real, proven shot (pun intended) everyone knows "can" work. Meaning we'll likely see Vyrologix used even a little earlier, which should help results. I'm sure many of the participants, especially early on, in our trial were getting involved because they were out of options and deep into their decline. If we catch them earlier I like our chances to improve on whatever the CD12 numbers show. And thus concludes my boring, science-y posts for the evening.